293 related articles for article (PubMed ID: 28956459)
1. Empirical antifungal treatment for diagnosed and undiagnosed invasive fungal disease in patients with hematologic malignancies.
Deng Q; Lv HR; Lin XM; Zhao MF; Geng L; Li YM
Curr Med Res Opin; 2018 Jul; 34(7):1209-1216. PubMed ID: 28956459
[TBL] [Abstract][Full Text] [Related]
2. Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study.
Wang L; Wang Y; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Front Med; 2019 Jun; 13(3):365-377. PubMed ID: 30604166
[TBL] [Abstract][Full Text] [Related]
3. Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in a Clinical Practice Setting in China.
Zhang X; Hu J; Hu Y; Huang H; Jin J; Li J; Liu Q; Shao Z; Wang J; Wang Q; Wu D; Huang X
Clin Ther; 2017 Sep; 39(9):1758-1768. PubMed ID: 28756883
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
5. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
[TBL] [Abstract][Full Text] [Related]
6. Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis.
Rodríguez-Veiga R; Montesinos P; Boluda B; Lorenzo I; Martínez-Cuadrón D; Salavert M; Pemán J; Calvillo P; Cano I; Acuña E; Villalba A; Piñana JL; Sanz J; Solves P; Senent L; Vicente A; Sempere A; Cervera J; Barragán E; Jarque I; Torres A; Sanz MA; Sanz GF
Ann Hematol; 2019 Sep; 98(9):2081-2088. PubMed ID: 31240471
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
8. [The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision)].
;
Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):754-763. PubMed ID: 32987477
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China.
Liu J; Huang H; Li Y; Liu L; Li J; Liu Z; Lu J; Ouyang J; Song Y; Zhou D; Ren H; Ma J; Wang C; Yu L; Zhou J; Wang J; Xiao Y; Huang X; Li J
Tumour Biol; 2016 Jun; 37(6):7893-900. PubMed ID: 26700667
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the implementation rate of primary antifungal prophylaxis and the prognosis of invasive fungal disease in acute leukemia patients in China.
Xu XH; Zhang L; Cao XX; Li J; Zhang W; Zhu TN; Cai HC; Chen M; Han X; Yang C; Han B; Zhang Y; Zhuang JL; Zhou DB; Duan MH
J Infect Chemother; 2017 Jun; 23(6):360-367. PubMed ID: 28341518
[TBL] [Abstract][Full Text] [Related]
11. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.
Herbrecht R; Caillot D; Cordonnier C; Auvrignon A; Thiébaut A; Brethon B; Michallet M; Mahlaoui N; Bertrand Y; Preziosi P; Ruiz F; Gorin NC; Gangneux JP
J Antimicrob Chemother; 2012 Nov; 67(11):2731-8. PubMed ID: 22850692
[TBL] [Abstract][Full Text] [Related]
12. Galactomannan in bronchoalveolar lavage for diagnosing invasive fungal disease.
Affolter K; Tamm M; Jahn K; Halter J; Passweg J; Hirsch HH; Stolz D
Am J Respir Crit Care Med; 2014 Aug; 190(3):309-17. PubMed ID: 25007380
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole prophylaxis--impact on incidence of invasive fungal disease and antifungal treatment in haematological patients.
Peterson L; Ostermann J; Rieger H; Ostermann H; Rieger CT
Mycoses; 2013 Nov; 56(6):651-8. PubMed ID: 23710592
[TBL] [Abstract][Full Text] [Related]
14. [The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the fifth revision)].
Chinese Invasive Fungal Infection Working Group
Zhonghua Nei Ke Za Zhi; 2017 Jun; 56(6):453-459. PubMed ID: 28592049
[TBL] [Abstract][Full Text] [Related]
15. Applicability of the EORTC/MSG criteria for IFD in clinical practice.
Rieger H; Lustig D; Barlow S; Ostermann H; Fiegl M; Peterson L; Rieger CT
Ann Hematol; 2015 May; 94(5):847-55. PubMed ID: 25544029
[TBL] [Abstract][Full Text] [Related]
16. Clinical risk score for predicting invasive fungal disease after allogeneic hematopoietic stem cell transplantation: Analysis of the China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study.
Sun Y; Hu J; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Transpl Infect Dis; 2021 Aug; 23(4):e13611. PubMed ID: 33825274
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of the prescription, consumption and costs of antifungal drugs in a pediatric hospital in Chile].
Barraza M; Barnafi N; Ortiz G; Torres JP; Coria P; Catalán P; Palma J; Morales J
Rev Chilena Infectol; 2018 Aug; 35(4):351-357. PubMed ID: 30534920
[TBL] [Abstract][Full Text] [Related]
18. Secondary antifungal prophylaxis in hematological malignancy patients with previous invasive fungal disease: a retrospective analysis.
Liu M; Li Y; Zhang Y; Zhao X; Zhai B; Zhang Q; Wang L; Zhao Y; Li H; Wang Q; Gao C; Huang W; Yu L
PLoS One; 2014; 9(12):e115461. PubMed ID: 25531544
[TBL] [Abstract][Full Text] [Related]
19. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
20. [Cross-sectional investigation of first-choice of antifungal agents in empirical and preemptive antifungal therapy for patients with hematological malignancies].
Ji Y; Xu LP; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):473-7. PubMed ID: 23827099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
